SI-BONE, Inc. (SIBN), a medical device firm, on Tuesday said that it will report fourth-quarter and full-year results after market close on February 23, and will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SI-BONE focuses on solutions to musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
In January, SI-BONE reported preliminary revenue growth of 15% revenue for the fourth quarter and a 20% increase in revenue for the full year. The quarterly revenue is expected to be in the range of $56.2 to $56.3 million, higher than$49.0 million in the prior year.
U.S.-based preliminary fourth-quarter revenue is expected to be in the range of $53.3 to $53.4 million, up 14% from $46.9 million a year ago.
Cash and equivalents were approximately $147.7 million in the fourth quarter.
For the full year 2025, preliminary revenue is expected to range between $200.8 and $200.9 million, up 20% from $167.18 million in the year-ago period.
Preliminary U.S. revenue for the full year is seen between $190.9 and $191.0 million, up 21% from $158.4 million in the prior year.
Since April 2025, SIBN has traded between $12.50 and $21.89. The stock had closed Monday's trade at $16.27, down 1.27%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.